With one simple experiment, University of Illinois chemists have debunked a widely held misconception about an often-prescribed drug.

A new formulation of Amphotericin B (AmB) developed by University of British Columbia researchers has been shown to be stable in tropical climates and effective in treating Visceral Leishmaniasis (VL) in mouse models.

By Thakur, C P Paromomycin, an aminoglycoside, is known to cause several side effects like nephrotoxicity and ototoxicity like other aminoglycosides but tetany has not been reported. Three cases of tetany were detected in the patients of kala-azar treated with paromomycin.

BioDelivery Sciences International has initiated its first Phase I clinical study assessing the safety, tolerability and pharmacokinetics of Bioral amphotericin B. This study is said to represent a significant step forward in the evaluation of BDSI's second drug delivery platform, known as Bioral.

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) has initiated its first Phase I clinical study assessing the safety, tolerability and pharmacokinetics of Bioral(R) Amphotericin B.